The first batch of specially appointed experts and professors of the country, professor at the School of Life Sciences of East China Normal University, director of the Institute of Life Medicine, former dean of the School of Life Sciences of East China Normal University, dean of the Institute of Science and Technology Conversion of East China Normal University Haifa University, and director of the Shanghai Key Laboratory of Regulating Biology.
As the chief scientist, I have successively presided over the National 973 Program and major scientific research programs, key projects of the National Natural Science Foundation, and major national new drug creation projects. I have published over 450 SCI papers in internationally renowned academic journals such as Cell, Science, Nature, Nature Medicine, and Nature Biotechnology, with more than 40000 citations, H-Index 105， For several consecutive years, he has been recognized as a highly cited scholar in China, with over 300 patent applications and more than 200 authorizations. Has won the National Science and Technology Progress First Prize, Shanghai Science and Technology Progress First Prize, Shanghai Magnolia Memorial Award, and East China Normal University Outstanding Academic Contribution Award. The new generation of non viral targeted integration PD1-CART developed in 2022 has been awarded the "Top Ten Research Advances in Chinese Hematology" and "China's Annual Major Medical Progress". The allogeneic universal CAR-T therapy for autoimmune diseases developed in 2024 has achieved the top ten scientific breakthroughs in Science, the best paper in Cell 2024, milestone papers in Cell journal from 2014 to 2024, the "Top Ten Advances in Chinese Life Sciences" in 2024, the "Top Ten Advances in Chinese Pharmaceutical Biotechnology" in 2024, and the "Top Ten Advances in Chinese Science" in 2024.